Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

67.74
Delayed Data
As of 4:00pm ET
 -3.09 / -4.36%
Today’s Change
51.67
Today|||52-Week Range
91.35
-3.66%
Year-to-Date
No recent news for Ultragenyx Pharmaceutical Inc.

Today’s Trading

Previous close70.83
Today’s open71.77
Day’s range66.90 - 71.77
Volume296,745
Average volume (3 months)491,742
Market cap$3.0B
Dividend yield--
Data as of 4:00pm ET, 07/27/2017

Growth & Valuation

Earnings growth (last year)-56.82%
Earnings growth (this year)-13.08%
Earnings growth (next 5 years)+51.01%
Revenue growth (last year)--
P/E ratioNM
Price/Sales20,927.50
Price/Book6.16

Competitors

 Today’s
change
Today’s
% change
GWPHGW Pharmaceuticals P...+1.00+0.86%
SAGESAGE Therapeutics In...-3.30-3.94%
HCMHutchison China Medi...-0.88-3.74%
AGIOAgios Pharmaceutical...-1.89-3.25%
Data as of 4:00pm ET, 07/27/2017

Financials

Next reporting dateAugust 16, 2017
EPS forecast (this quarter)-$1.72
Annual revenue (last year)$133.0K
Annual profit (last year)-$245.9M
Net profit margin-184,867.67%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Emil D. Kakkis
Chief Financial Officer &
Executive Vice President
Shalini Sharp
Corporate headquarters
Novato, California

Forecasts